5 completed, 2 terminated, 1 unknown. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Terminated 2, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow ALV003: new trials by email Literature Review of ALV003 trials Research Report on ALV003
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Latiglutenase in T1D/CD Patients Latiglutenase, Placebo - Celiac Disease | Phase 2 | Terminated | Entero Therapeutics | 13 | 2021-04-06 | 2024-08-05 |
| Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients Latiglutenase, Placebo - Celiac Disease | Phase 2 | Terminated | Entero Therapeutics | 83 | 2019-11-01 | 2024-08-05 |
| Latiglutenase as a Treatment for Celiac Disease Latiglutenase, Placebo - Celiac Disease | Phase 2 | Completed | Immunogenics, LLC | 79 | 2019-03-01 | 2021-12-15 |
| Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients ALV003, placebo - Celiac Disease | Phase 2 | Unknown | Alvine Pharmaceuticals Inc. | 500 | 2013-08-01 | 2014-12-17 |
| Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease ALV003, ALV003 placebo - Celiac Disease | Phase 2 | Completed | Alvine Pharmaceuticals Inc. | 61 | 2010-11-01 | 2012-08-06 |
| Safety and Efficacy of ALV003 for the Treatment of Celiac Disease ALV003, ALV003 placebo - Celiac Disease | Phase 2 | Completed | Alvine Pharmaceuticals Inc. | 74 | 2009-08-01 | 2012-08-06 |
| Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal ALV003, Placebo - Celiac Disease | Phase 1 | Completed | Alvine Pharmaceuticals Inc. | 36 | 2008-03-01 | 2010-02-19 |
| A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease 4 dose levels of ALV003 - Celiac Disease | Phase 1 | Completed | Alvine Pharmaceuticals Inc. | 28 | 2008-02-01 | 2009-08-18 |
Celiac Disease (8)
Alvine Pharmaceuticals Inc. (5) · Entero Therapeutics (2) · Immunogenics, LLC (1)
United States (6) · Finland (3) · Canada (1) · Ireland (1) · Norway (1) · United Kingdom (1)
Joseph Murray, MD (2) · Vijaya Pratha, MD (2) · Daniel Adelman, MD (1) · David Maahs, MD (1)
PMID 24583059, PMID 27864127, PMID 28755266, PMID 35931103
R33AT009637 (1), R44DK121606 (1), U44AI134590 (1)